[1]Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19[J]. New England Journal of Medicine, 2022, 386(15): 1397-1408.
[2]Jayk Bernal A, Gomes da Silva M M, Musungaie D B, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients[J]. New England Journal of Medicine, 2022, 386(6): 509-520.
[3]Gray E J, Nguyen-Van-Tam J S. Molnupiravir for SARS-CoV-2 infection: Public health and policy implications[J]. Journal of Infection, 2022.
[4]Wong C K H, Au I C H, Lau K T K, et al. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study[J]. The Lancet, 2022, 400(10359): 1213-1222.
[5]Yu B, Chang J. The first Chinese oral anti-COVID-19 drug Azvudine launched[J]. The Innovation, 2022, 3(6): 100321.
[6]https:///ct2/show/results/NCT05033145
[7]https:///ct2/show/results/NCT05642910
[8]https:///ct2/show/NCT05033145?term=AZVUDINE&draw=2&rank=2
[9]张福杰,王卓,王全红等.新型冠状病毒感染者抗病毒治疗专家共识[J].中华临床感染病杂志2023.16(1):10-20.DOI:10.3760/cma.j.issn.1674-2397.2023.01.002